Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;28(10):1382-1388.
doi: 10.1016/j.cmi.2022.05.009. Epub 2022 May 17.

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis

Matías J Pereson  1 , Lucas Amaya  2 , Karin Neukam  3 , Patricia Baré  4 , Natalia Echegoyen  2 , María Noel Badano  4 , Alicia Lucero  2 , Antonella Martelli  2 , Gabriel H Garcia  5 , Cristina Videla  2 , Alfredo P Martínez  2 , Federico A Di Lello  6
Affiliations

Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis

Matías J Pereson et al. Clin Microbiol Infect. 2022 Oct.

Abstract

Objectives: To compare the homologous prime-boost vaccination scheme of Gam-COVID-Vac (Sputnik V (SpV)) to its heterologous combination with mRNA-1273 (Moderna (Mod)) vaccine.

Methods: SARS-CoV-2 anti-spike (S)-receptor binding domain (RBD) IgG concentration was assessed three to seven weeks after complete vaccination. Reactogenicity was evaluated by declared side events and medical assistance required until day 7 post boost.

Results: Of 190 participants enrolled, 105 received homologous SpV/SpV and the remaining heterologous SpV/Mod vaccination scheme, respectively. Median (interquartile range (IQR)) age was 54 (37-63) years, 132 out of 190 (69.5%) were female, and 46 out of 190 (24.2%) individuals had a prior confirmed COVID-19. Anti-S-RBD IgG median (IQR) titers were significantly higher for SpV/Mod (2511 (1476-3992) binding antibody units (BAU)/mL) than for SpV/SpV (582 (209-1609) BAU/mL; p < 0.001] vaccination scheme. In a linear model adjusted for age, gender, time to the serological assay, and time between doses, SpV/Mod (4.154 (6.585-615.554); p < 0.001] and prior COVID (3.732 (8.641-202.010); p < 0.001) were independently associated with higher anti-S-RBD IgG values. A higher frequency of mild and moderate adverse effects was associated with the heterologous scheme (20 of 85 (23.5%) vs. 13 of 105 (12.4%); p = 0.043 and 27 of 85 (31.8%) vs. 14 of 105 (13.3%); p = 0.002), respectively, although it was well tolerated by all individuals and no medical assistance was required.

Discussion: The heterologous SpV/Mod combination against SARS-CoV-2 is well tolerated and significantly increases humoral immune response as compared to the homologous SpV/SpV immunization.

Keywords: Gam-COVID-Vac; Heterologous scheme; SARS-CoV-2; Vaccine; mRNA-1273.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Anti-S-RBD IgG levels for homologous (SpV/SpV) and heterologous (SpV/Mod) scheme vaccinated subjects who had (a) or had not (b) a confirmed SARS-CoV-2 infection prior to vaccination. Abbreviations: BAU, binding antibody units; Mod, Moderna; RBD, receptor binding domain, S, spike; SpV, Sputnik V.
Fig. 2
Fig. 2
Reactogenicity: frequency of participants' reported local and systemic adverse effects for the Sputnik V/Sputnik V and Sputnik V/Moderna schemes, classified by severity.
See this image and copyright information in PMC

Comment in

References

    1. European Medicines Agency . AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. 2021. https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-find... Apr 7 [cited 2022 Feb 9]. Available at:
    1. European Medicines Agency . COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis. 2021. https://www.ema.europa.eu/en/news/covid-19-vaccines-update-ongoing-evalu... Jun 11 [cited 2022 Feb 9]. Available from:
    1. Borobia A.M., Carcas A.J., Pérez-Olmeda M., Castaño L., Bertran M., García-Pérez J., et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398:121–130. doi: 10.1016/S0140-6736(21)01420-3. - DOI - PMC - PubMed
    1. Fabricius D., Ludwig C., Scholz J., Rode I., Tsamadou C., Jacobsen E., et al. mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects. Vaccines. 2021;9:918. doi: 10.3390/vaccines9080918. - DOI - PMC - PubMed
    1. Hillus D., Schwarz T., Tober-Lau P., Vanshylla K., Hastor H., Thibeault C., et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet. 2021;9:1255–1265. doi: 10.1016/S2213-2600(21)00357-X. - DOI - PMC - PubMed